CURX net incomeQ2 2026-$3.29M
CURX net income was -$3.29M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$60.3K a year earlier. For the full fiscal 2025 it was -$4.23M, compared with -$361.5K in fiscal 2024.
Curanex Pharmaceuticals Inc (CURX) financials
For the twelve months ended Jun 30, 2026, Curanex Pharmaceuticals Inc reported -$10.47M of net income.
- Net income, TTM
- -$10.47M
- EPS, diluted, TTM
- -$0.39
- Cash
- $2.94M
- Market cap
- $9.7M
FY2024FY2025
CURX revenue and earnings growth
CURX EPSQ2 2026-$0.12
CURX diluted EPS was -$0.12 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0.00 a year earlier. For the full fiscal 2025 it was -$0.17.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Research and development | $2.99M | - |
| Selling, general and admin | $1.25M | $290.4K |
| Operating income | -$4.24M | -$365.1K |
| Interest expense | $8.5K | - |
| Net income | -$4.23M | -$361.5K |
| EPS, basic | -$0.17 | -$0.03 |
| EPS, diluted | -$0.17 | -$0.03 |
| Diluted shares | 25.5M | 13.3M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash and equivalents | $4.97M | $148.9K |
| Current assets | $11.23M | $517.9K |
| Total assets | $11.58M | $517.9K |
| Current liabilities | $137.0K | $14.6K |
| Total liabilities | $361.0K | $14.6K |
| Shareholders' equity | $11.22M | $503.4K |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Operating cash flow | -$10.48M | -$555.6K |
| Financing cash flow | $15.31M | $630.1K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $2.59M | $2.26M | $2.31M | $677.5K | - | - | - | - | - | - |
| Selling, general and admin | $731.8K | $927.2K | $786.3K | $273.9K | $57.7K | $137.5K | $72.7K | $93.3K | $44.2K | $80.2K |
| Operating income | -$3.33M | -$3.18M | -$3.09M | -$951.3K | -$57.7K | -$137.5K | -$147.4K | -$93.3K | -$44.2K | -$80.2K |
| Interest expense | - | - | $0 | $4.1K | $3.1K | $1.4K | - | - | - | - |
| Net income | -$3.29M | -$3.15M | -$3.07M | -$954.1K | -$60.3K | -$137.6K | -$145.9K | -$91.2K | -$44.2K | -$80.2K |
| EPS, basic | -$0.12 | -$0.11 | -$0.12 | -$0.04 | $0.00 | -$0.01 | - | -$0.04 | -$0.02 | - |
| EPS, diluted | -$0.12 | -$0.11 | -$0.12 | -$0.04 | $0.00 | -$0.01 | - | -$0.04 | -$0.02 | - |
| Diluted shares | 28.4M | 28.3M | - | 25.6M | 24.0M | 24.0M | - | 2.4M | 2.4M | - |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.94M | $4.00M | $4.97M | $5.80M | $108.9K | - | $148.9K | - | - | - |
| Current assets | $4.79M | $8.09M | $11.23M | $14.42M | $711.3K | - | $517.9K | - | - | - |
| Total assets | $5.07M | $8.41M | $11.58M | $14.48M | $787.2K | - | $517.9K | - | - | - |
| Current liabilities | $104.3K | $128.7K | $137.0K | $186.0K | $75.9K | - | $14.6K | - | - | - |
| Total liabilities | $286.3K | $332.6K | $361.0K | $186.0K | $481.7K | - | $14.6K | - | - | - |
| Shareholders' equity | $4.79M | $8.08M | $11.22M | $14.29M | $305.4K | $365.8K | $503.4K | $624.2K | $715.2K | $129.9K |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.08M | -$954.6K | -$857.4K | -$9.19M | -$290.1K | -$149.9K | -$95.4K | -$129.9K | - | - |
| Financing cash flow | - | - | $0 | $14.91M | $200.0K | $200.0K | $0 | $0 | - | - |
| Stock-based compensation | $0 | $9.8K | - | - | - | - | - | - | - | - |
Key ratios
Source: XBRL data Curanex Pharmaceuticals Inc files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CURX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CURX | - | - | -$10.47M | - | $9.7M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
CURX FAQ
5 questionsIs CURX profitable?
No. Curanex Pharmaceuticals Inc reported a net loss of $10.47M for the twelve months ended Jun 30, 2026.How much cash and debt does CURX have?
Curanex Pharmaceuticals Inc reported $2.94M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is CURX earnings per share?
Diluted earnings per share were -$0.39 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did CURX last report financial results?
The latest statements here come from Curanex Pharmaceuticals Inc's 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this CURX financial data come from?
Quantisnow builds these statements from the structured XBRL data Curanex Pharmaceuticals Inc files with the SEC. It is provided for information only and is not investment advice.